Abstract
Inhibition of the type I IGF receptor (IGF1R) has been the focus of numerous clinical trials. Two reports in this issue describe the results of phase I trials of an IGF1R tyrosine kinase inhibitor OSI-906. This commentary will describe the complex endocrine changes induced by these types of agents. See related articles by Jones et al., p. 693, and Puzanov et al., p.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 667-669 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 21 |
| Issue number | 4 |
| DOIs | |
| State | Published - Feb 15 2015 |
Bibliographical note
Publisher Copyright:© -2014 American Association for Cancer Research.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'A tale of two receptors:Insulin and insulin-like growth factor signaling in cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS